Natural History and Prognosis of Chronic Hepatitis B Patients in the Indeterminate Phase

In chronic hepatitis B (CHB), an indeterminate phase exists outside the typical predefined phases. Our study investigates this indeterminate phase's natural history and prognosis, focusing on antiviral treatment outcomes. We conducted a retrospective cohort study to compare the risk of transiti...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology and hepatology 2024-12
Main Authors: Jiang, Hao, Yu, Hongsheng, Huang, Yinan, Li, Mingkai, Yang, Bilan, Xi, Xiaoli, Lei, Yiming, Wu, Bin, Yang, Yidong
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c900-2436d03f4f061c5293ea072a51f032f94b09eb26f35ed58dd841c28cee553f523
container_end_page
container_issue
container_start_page
container_title Journal of gastroenterology and hepatology
container_volume
creator Jiang, Hao
Yu, Hongsheng
Huang, Yinan
Li, Mingkai
Yang, Bilan
Xi, Xiaoli
Lei, Yiming
Wu, Bin
Yang, Yidong
description In chronic hepatitis B (CHB), an indeterminate phase exists outside the typical predefined phases. Our study investigates this indeterminate phase's natural history and prognosis, focusing on antiviral treatment outcomes. We conducted a retrospective cohort study to compare the risk of transitioning to immune active phase between inactive and indeterminate CHB and the incidence of hepatocellular carcinoma (HCC) and cirrhosis between untreated patients with indeterminate CHB (at baseline and throughout follow-up) and those who received treatment, following standard AASLD 2018 guidance. The risk of transitioning to the immune active phase over 3, 5, and 10 years was 6.3%, 8.9%, and 14.2%, respectively, for inactive phase patients (n = 104). For HBeAg-negative indeterminate phase patients (n = 194), the risk was significantly higher at 23.0%, 31.9%, and 38.2%, and for HBeAg-positive indeterminate phase patients (n = 140), it was 40.4%, 52.0%, and 55.0% (p 
doi_str_mv 10.1111/jgh.16849
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3146948944</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3146948944</sourcerecordid><originalsourceid>FETCH-LOGICAL-c900-2436d03f4f061c5293ea072a51f032f94b09eb26f35ed58dd841c28cee553f523</originalsourceid><addsrcrecordid>eNo9kLFOwzAURS0EoqUw8APIIwwpz7GdxiNUQCtV0KEDW-Qmz42r1Cm2M_TvCbRwl3f1dHSHQ8gtgzHr87jd1GOW5UKdkSETAhI2Edk5GULOZKI4UwNyFcIWAARM5CUZcJUpUAKG5PNdx87rhs5siK0_UO0quvTtxrXBBtoaOq1962xJZ7jX0cb--UyXfUMXA7WOxhrp3FUY0e-s0xHpstYBr8mF0U3Am9MdkdXry2o6SxYfb_Pp0yIpFUCSCp5VwI0wkLFSpoqjhkmqJTPAU6PEGhSu08xwiZXMqyoXrEzzElFKbmTKR-T-OLv37VeHIRY7G0psGu2w7ULBmciUyJUQPfpwREvfhuDRFHtvd9ofCgbFj8ei91j8euzZu9Nst95h9U_-iePfusdtEw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3146948944</pqid></control><display><type>article</type><title>Natural History and Prognosis of Chronic Hepatitis B Patients in the Indeterminate Phase</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Jiang, Hao ; Yu, Hongsheng ; Huang, Yinan ; Li, Mingkai ; Yang, Bilan ; Xi, Xiaoli ; Lei, Yiming ; Wu, Bin ; Yang, Yidong</creator><creatorcontrib>Jiang, Hao ; Yu, Hongsheng ; Huang, Yinan ; Li, Mingkai ; Yang, Bilan ; Xi, Xiaoli ; Lei, Yiming ; Wu, Bin ; Yang, Yidong</creatorcontrib><description>In chronic hepatitis B (CHB), an indeterminate phase exists outside the typical predefined phases. Our study investigates this indeterminate phase's natural history and prognosis, focusing on antiviral treatment outcomes. We conducted a retrospective cohort study to compare the risk of transitioning to immune active phase between inactive and indeterminate CHB and the incidence of hepatocellular carcinoma (HCC) and cirrhosis between untreated patients with indeterminate CHB (at baseline and throughout follow-up) and those who received treatment, following standard AASLD 2018 guidance. The risk of transitioning to the immune active phase over 3, 5, and 10 years was 6.3%, 8.9%, and 14.2%, respectively, for inactive phase patients (n = 104). For HBeAg-negative indeterminate phase patients (n = 194), the risk was significantly higher at 23.0%, 31.9%, and 38.2%, and for HBeAg-positive indeterminate phase patients (n = 140), it was 40.4%, 52.0%, and 55.0% (p &lt; 0.001). Inverse probability of treatment weighting (IPTW) was utilized to balance the groups of treated and untreated indeterminate patients. Following IPTW adjustment, the Kaplan-Meier curve analysis indicates that the risk of HCC and cirrhosis among untreated patients (n = 294) is higher than that among treated patients (n = 76), (p = 0.015 and 0.007, respectively). In the multivariable analysis, antiviral therapy remained an independent predictor of a reduced risk of HCC (aHR 0.128, 95% CI 0.031-0.522, p = 0.005) and cirrhosis (aHR 0.148, 95% CI 0.044-0.496, p = 0.002). The indeterminate phase patients had a high-risk transition to active phase, and antiviral therapy can reduce the incidence of developing HCC and cirrhosis.</description><identifier>ISSN: 0815-9319</identifier><identifier>ISSN: 1440-1746</identifier><identifier>EISSN: 1440-1746</identifier><identifier>DOI: 10.1111/jgh.16849</identifier><identifier>PMID: 39690940</identifier><language>eng</language><publisher>Australia</publisher><ispartof>Journal of gastroenterology and hepatology, 2024-12</ispartof><rights>2024 Journal of Gastroenterology and Hepatology Foundation and John Wiley &amp; Sons Australia, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c900-2436d03f4f061c5293ea072a51f032f94b09eb26f35ed58dd841c28cee553f523</cites><orcidid>0000-0002-3892-1687 ; 0000-0001-9039-9681</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39690940$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jiang, Hao</creatorcontrib><creatorcontrib>Yu, Hongsheng</creatorcontrib><creatorcontrib>Huang, Yinan</creatorcontrib><creatorcontrib>Li, Mingkai</creatorcontrib><creatorcontrib>Yang, Bilan</creatorcontrib><creatorcontrib>Xi, Xiaoli</creatorcontrib><creatorcontrib>Lei, Yiming</creatorcontrib><creatorcontrib>Wu, Bin</creatorcontrib><creatorcontrib>Yang, Yidong</creatorcontrib><title>Natural History and Prognosis of Chronic Hepatitis B Patients in the Indeterminate Phase</title><title>Journal of gastroenterology and hepatology</title><addtitle>J Gastroenterol Hepatol</addtitle><description>In chronic hepatitis B (CHB), an indeterminate phase exists outside the typical predefined phases. Our study investigates this indeterminate phase's natural history and prognosis, focusing on antiviral treatment outcomes. We conducted a retrospective cohort study to compare the risk of transitioning to immune active phase between inactive and indeterminate CHB and the incidence of hepatocellular carcinoma (HCC) and cirrhosis between untreated patients with indeterminate CHB (at baseline and throughout follow-up) and those who received treatment, following standard AASLD 2018 guidance. The risk of transitioning to the immune active phase over 3, 5, and 10 years was 6.3%, 8.9%, and 14.2%, respectively, for inactive phase patients (n = 104). For HBeAg-negative indeterminate phase patients (n = 194), the risk was significantly higher at 23.0%, 31.9%, and 38.2%, and for HBeAg-positive indeterminate phase patients (n = 140), it was 40.4%, 52.0%, and 55.0% (p &lt; 0.001). Inverse probability of treatment weighting (IPTW) was utilized to balance the groups of treated and untreated indeterminate patients. Following IPTW adjustment, the Kaplan-Meier curve analysis indicates that the risk of HCC and cirrhosis among untreated patients (n = 294) is higher than that among treated patients (n = 76), (p = 0.015 and 0.007, respectively). In the multivariable analysis, antiviral therapy remained an independent predictor of a reduced risk of HCC (aHR 0.128, 95% CI 0.031-0.522, p = 0.005) and cirrhosis (aHR 0.148, 95% CI 0.044-0.496, p = 0.002). The indeterminate phase patients had a high-risk transition to active phase, and antiviral therapy can reduce the incidence of developing HCC and cirrhosis.</description><issn>0815-9319</issn><issn>1440-1746</issn><issn>1440-1746</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kLFOwzAURS0EoqUw8APIIwwpz7GdxiNUQCtV0KEDW-Qmz42r1Cm2M_TvCbRwl3f1dHSHQ8gtgzHr87jd1GOW5UKdkSETAhI2Edk5GULOZKI4UwNyFcIWAARM5CUZcJUpUAKG5PNdx87rhs5siK0_UO0quvTtxrXBBtoaOq1962xJZ7jX0cb--UyXfUMXA7WOxhrp3FUY0e-s0xHpstYBr8mF0U3Am9MdkdXry2o6SxYfb_Pp0yIpFUCSCp5VwI0wkLFSpoqjhkmqJTPAU6PEGhSu08xwiZXMqyoXrEzzElFKbmTKR-T-OLv37VeHIRY7G0psGu2w7ULBmciUyJUQPfpwREvfhuDRFHtvd9ofCgbFj8ei91j8euzZu9Nst95h9U_-iePfusdtEw</recordid><startdate>20241218</startdate><enddate>20241218</enddate><creator>Jiang, Hao</creator><creator>Yu, Hongsheng</creator><creator>Huang, Yinan</creator><creator>Li, Mingkai</creator><creator>Yang, Bilan</creator><creator>Xi, Xiaoli</creator><creator>Lei, Yiming</creator><creator>Wu, Bin</creator><creator>Yang, Yidong</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3892-1687</orcidid><orcidid>https://orcid.org/0000-0001-9039-9681</orcidid></search><sort><creationdate>20241218</creationdate><title>Natural History and Prognosis of Chronic Hepatitis B Patients in the Indeterminate Phase</title><author>Jiang, Hao ; Yu, Hongsheng ; Huang, Yinan ; Li, Mingkai ; Yang, Bilan ; Xi, Xiaoli ; Lei, Yiming ; Wu, Bin ; Yang, Yidong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c900-2436d03f4f061c5293ea072a51f032f94b09eb26f35ed58dd841c28cee553f523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jiang, Hao</creatorcontrib><creatorcontrib>Yu, Hongsheng</creatorcontrib><creatorcontrib>Huang, Yinan</creatorcontrib><creatorcontrib>Li, Mingkai</creatorcontrib><creatorcontrib>Yang, Bilan</creatorcontrib><creatorcontrib>Xi, Xiaoli</creatorcontrib><creatorcontrib>Lei, Yiming</creatorcontrib><creatorcontrib>Wu, Bin</creatorcontrib><creatorcontrib>Yang, Yidong</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jiang, Hao</au><au>Yu, Hongsheng</au><au>Huang, Yinan</au><au>Li, Mingkai</au><au>Yang, Bilan</au><au>Xi, Xiaoli</au><au>Lei, Yiming</au><au>Wu, Bin</au><au>Yang, Yidong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Natural History and Prognosis of Chronic Hepatitis B Patients in the Indeterminate Phase</atitle><jtitle>Journal of gastroenterology and hepatology</jtitle><addtitle>J Gastroenterol Hepatol</addtitle><date>2024-12-18</date><risdate>2024</risdate><issn>0815-9319</issn><issn>1440-1746</issn><eissn>1440-1746</eissn><abstract>In chronic hepatitis B (CHB), an indeterminate phase exists outside the typical predefined phases. Our study investigates this indeterminate phase's natural history and prognosis, focusing on antiviral treatment outcomes. We conducted a retrospective cohort study to compare the risk of transitioning to immune active phase between inactive and indeterminate CHB and the incidence of hepatocellular carcinoma (HCC) and cirrhosis between untreated patients with indeterminate CHB (at baseline and throughout follow-up) and those who received treatment, following standard AASLD 2018 guidance. The risk of transitioning to the immune active phase over 3, 5, and 10 years was 6.3%, 8.9%, and 14.2%, respectively, for inactive phase patients (n = 104). For HBeAg-negative indeterminate phase patients (n = 194), the risk was significantly higher at 23.0%, 31.9%, and 38.2%, and for HBeAg-positive indeterminate phase patients (n = 140), it was 40.4%, 52.0%, and 55.0% (p &lt; 0.001). Inverse probability of treatment weighting (IPTW) was utilized to balance the groups of treated and untreated indeterminate patients. Following IPTW adjustment, the Kaplan-Meier curve analysis indicates that the risk of HCC and cirrhosis among untreated patients (n = 294) is higher than that among treated patients (n = 76), (p = 0.015 and 0.007, respectively). In the multivariable analysis, antiviral therapy remained an independent predictor of a reduced risk of HCC (aHR 0.128, 95% CI 0.031-0.522, p = 0.005) and cirrhosis (aHR 0.148, 95% CI 0.044-0.496, p = 0.002). The indeterminate phase patients had a high-risk transition to active phase, and antiviral therapy can reduce the incidence of developing HCC and cirrhosis.</abstract><cop>Australia</cop><pmid>39690940</pmid><doi>10.1111/jgh.16849</doi><orcidid>https://orcid.org/0000-0002-3892-1687</orcidid><orcidid>https://orcid.org/0000-0001-9039-9681</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0815-9319
ispartof Journal of gastroenterology and hepatology, 2024-12
issn 0815-9319
1440-1746
1440-1746
language eng
recordid cdi_proquest_miscellaneous_3146948944
source Wiley-Blackwell Read & Publish Collection
title Natural History and Prognosis of Chronic Hepatitis B Patients in the Indeterminate Phase
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A38%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Natural%20History%20and%20Prognosis%20of%20Chronic%20Hepatitis%20B%20Patients%20in%20the%20Indeterminate%20Phase&rft.jtitle=Journal%20of%20gastroenterology%20and%20hepatology&rft.au=Jiang,%20Hao&rft.date=2024-12-18&rft.issn=0815-9319&rft.eissn=1440-1746&rft_id=info:doi/10.1111/jgh.16849&rft_dat=%3Cproquest_cross%3E3146948944%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c900-2436d03f4f061c5293ea072a51f032f94b09eb26f35ed58dd841c28cee553f523%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3146948944&rft_id=info:pmid/39690940&rfr_iscdi=true